Clinical trial NCT02572492: Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support
Official title: Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: Multiple Myeloma
Recurrence
Carfilzomib
Salvage Therapy
Transplantation, Autologous
Lead sponsor: Aalborg University Hospital
Sponsor class: OTHER
Collaborators: name: Nordic Myeloma Study Group
First posted: 2015-10-09
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates induction therapy with carfilzomib-cyclophosphamide-dexamethasone before salvage high-dose melphalan with autologous stem cell support (HDT) in multiple myeloma patients with relapse after HDT done at diagnosis. In addition, the study evaluates the effect of maintenance therapy after salvage HDT in multiple myeloma. After salvage HDT half of the patients receive maintenance therapy with carfilzomib/dexamethasone while the other half are observed without maintenance therapy.

Detailed description: The survival in younger myeloma patients improved in the nineties with the introduction of high-dose melphalan with autologous stem cell support (HDT) and despite the emergence of novel therapies HDT remains a keystone in myeloma treatment. However, all patients will eventually experience relapse after HDT performed at diagnosis. Eligible patients with late relapse are considered for salvage HDT. The duration of response after salvage HDT is in most studies reported to be approximately half the length of the response after initial HDT. The choice of induction treatment before HDT might affect the outcome after the induction therapy as well as the outcome after the HDT. In other settings the novel proteasome inhibitor Carfilzomib has showed superiority to the first-in-class proteasome inhibitor bortezomib. In addition, carfilzomib has a favourable profile of side effects. Thus, the aim of this phase 2 study is to evaluate induction therapy with carfilzomib-cyclophosphamide-dexamethasone before salvage HDT. The primary end-point in this part of the study is comparison of time to progression after the initial HDT and time to progression after salvage HDT when four series of carfilzomib-cyclophosphamide-dexamethasone are used as induction therapy. In the study Carfilzomib is also included in the conditioning regimen with administration of Iv carfilzomib 27 mg/sqm on day -2 and -1. The standard conditioning regime consists of Iv melphalan 200 mg/sqm on day -2 and reinfusion of at least 2.0 x 10m CD34+ stem cells/kg body weight on day 0.

The purpose of maintenance therapy in multiple myeloma is to prolong the time to progression of disease. There are limited data on the impact of maintenance therapy after salvage HDT. Another important aim of the study is therefore to evaluate the effect of carfilzomib/dexamethasone given every other week compared to observation without maintenance therapy. This part of the study starts two months after HDT. The randomization is stratified according to relapse 1 - 2 years or \> 2 years after HDT, ISS stage and standard versus high-risk cytogenetics. The primary end-point of this part of the study is comparison of time to progression in carfilzomib-dexamethasone maintenance arm and in the observational arm. Patients will continue on maintenance therapy/observation until progression, end of study or fulfil standard criteria for discontinuation of treatment according to the protocol.

The study will include 200 patients with relapse of multiple myeloma more than one year after initial HDT. It is a prerequisite that the patients have at least 2.0 x 10m CD34+ stem cells/kg body weight saved in the freezer. The study is conducted by the Nordic Myeloma Study Group (NMSG) at clinics in Denmark, Sweden, Norway, Finland and Lithuania. The first patient was included in January 2015 and enrolment is expected to continue until December 2017. The study ends when the last included patient has been followed for 9 months after randomization.

Eligibility criteria: Inclusion Criteria:

* Myeloma diagnosis according to IMWG criteria
* First treatment demanding relapse after HDT according to IMWG criteria
* More than 2.0 x 10m CD34+ stem cells / kg body weight in the freezer for stem cell support
* Signed informed consent given prior to any study related activities have been performed
* Age \> 18 years

Exclusion Criteria:

Demographic

* Allogeneic transplantation scheduled as a part of the treatment
* Treatment demanding relapse less than one year after HDT
* Myeloma treatment after the first HDT, except radiotherapy, bisphosphonates, denosumab and corticosteroids less than 6 days for symptom control
* Patients not having received HDT as first line treatment
* Previous treatment with carfilzomib
* Expected survival of less than six months
* Performance status (WHO) ≥ 3

Laboratory

* Serum M-component \< 5 g/l and urine M-component \< 200 mg/l
* Any of the following laboratory abnormalities:

  * Absolute neutrophil count (ANC) \< 1.0 × 109/L
  * Hemoglobin \< 5 mmol/L (\<80 g/L) (prior RBC transfusion or recombinant human erythropoietin use is permitted)
  * Platelet count \< 50 × 109/L (\< 30 × 109/L if myeloma involvement in the bone marrow is \> 50%)
  * Serum ALT or AST \> 3.5 times the upper limit of normal and serum direct bilirubin \> 34 µmol/L (2 mg/dL)
  * Creatinine clearance (CrCl) \< 15 mL/minute, either measured or calculated using a standard formula

Concurrent conditions

* Concurrent disease making treatment with carfilzomib, cyclophosphamide or dexamethasone unsuitable
* Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrolment
* Major surgery within 21 days prior to enrolment
* Acute active infection requiring treatment
* Known or suspected hypersensitivity or intolerance to melphalan, dexamethasone or Captisol® (a cyclodextrin derivative)
* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, NYHA Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, uncontrolled severe arrhythmias, or cardiac amyloidosis
* LVEF \<40%, determined by 2-D transthoracic echocardiogram (ECHO) or Multigated Acquisition Scan (MUGA)
* Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrolment
* Serious hepatic disorder, including active hepatitis B or C infection
* Other serious medical or psychiatric illness likely to interfere with participation in this clinical study
* Use of any investigational agents or experimental medical device within 28 days prior to enrolment into the study

Ethical/other

* Pregnant or lactating females
* Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception
* Male subjects must agree to practice contraception

Primary outcomes:
measure: Comparison of time to progression after high-dose melphalan with stem cell support (HDT) performed at diagnosis and time to progression after a salvage HDT combined with carfilzomib-cyclophosphamide-dexamethasone
timeFrame: 3 years
measure: Comparison of time to progression between carfilzomib-dexamethasone maintenance and observation in patients treated with salvage HDT.
timeFrame: 3 years
Secondary outcomes:
measure: Adverse events assessed by CTCAE v4.0 in carfilzomib-cyclophosphamide-dexamethasone induction regime and carfilzomib as part of the high-dose melphalan conditioning
timeFrame: 5 months
measure: Response rates of carfilzomib-cyclophosphamide-dexamethasone induction therapy and HDT
timeFrame: 5 months
measure: Time to marrow regeneration (neutrophil- and platelet recovery) after the HDT
timeFrame: 3 weeks
measure: Adverse events assessed by CTCAE v4.0 in maintenance treatment with carfilzomib-dexamethasone
timeFrame: 3 years
measure: Comparison of overall survival between carfilzomib-dexamethasone maintenance and observation in patients treated with a salvage HDT
timeFrame: 3 years
measure: Quality of life assessed by EORTC QLQ-MY20 and EORTC QLQ-C30
timeFrame: 3 years
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg University Hospital
city: Turku
country: Finland
facility: Turku University Hospital
city: Vilnius
country: Lithuania
facility: Vilnius University hospital "Santariskiu Clinics"
city: Oslo
country: Norway
facility: Oslo University Hospital
city: Lund
country: Sweden
facility: Skåne University Hospital
Study officials:
affiliation: Aalborg University Hospital
name: Henrik Gregersen, MD
role: PRINCIPAL_INVESTIGATOR
References: